Hypertrophic Cardiomyopathy (HCM)MAP HCMNCT07454135
Mechanisms of Atrial Pathoelectrophysiology in HCM
An observational study of Hypertrophic Cardiomyopathy (HCM) and Atrial Fibrillation (AF), run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF)
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 May 2026to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.
Who may be able to join
- Paroxysmal or persistent atrial fibrillation
- Diagnosis of hypertrophic cardiomyopathy
- Patient planning to proceed to atrial fibrillation ablation following clinical consultation
- Age 18-80 years
- Able and willing to provide written informed consent
- Able and willing to comply with study follow up requirements
Who cannot join
- Any clinical contra-indication to ablation
- Any disease limiting life expectancy to <1 year
- Potential participant currently pregnant or breast feeding
- Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
- Unable to understand verbal or written explanations given in English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Guy's and St Thomas' NHS Foundation Trust
London
Magdalena Klis, 02071887188, magda.klis@kcl.ac.uk
About this study
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
- Keywords
- hypertrophic cardiomyopathy, atrial fibrillation
- Medical subject headings
- Cardiomyopathy, Hypertrophic, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with HCM and AF | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts
Measured: At the time of the clinical ablation procedure
Secondary outcomes (2)
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .
Measured: At the time of clinical ablation procedure
Reduction in AF inducibility in silico models following simulated ablation
Measured: Based on measurements taken during the clinical ablation procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start26 May 2026
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertrophic Cardiomyopathy (HCM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- King's College London
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07454135
- Sponsor's protocol ID
- 339394
- Acronym
- MAP HCM
- Status last verified
- Mar 2026
- First submitted
- 2 Mar 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanisms of Atrial Pathoelectrophysiology in HCM
- ClinicalTrials.gov ID
- NCT07454135
- Acronym / sponsor ID
- MAP HCM / 339394
- Keywords
- hypertrophic cardiomyopathy, atrial fibrillation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Guy's and St Thomas' NHS Foundation TrustUniversity, hospital or other
- Collaborators
- King's College London
- Study start
- 26 May 2026 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with HCM and AF | – | – |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.
Key inclusion criteria (6 listed)
- Paroxysmal or persistent atrial fibrillation
- Diagnosis of hypertrophic cardiomyopathy
- Patient planning to proceed to atrial fibrillation ablation following clinical consultation
- Age 18-80 years
- Able and willing to provide written informed consent
Key exclusion criteria (5 listed)
- Any clinical contra-indication to ablation
- Any disease limiting life expectancy to <1 year
- Potential participant currently pregnant or breast feeding
- Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
- Unable to understand verbal or written explanations given in English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts
Time frame: At the time of the clinical ablation procedure
2 secondary outcomes
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .
Time frame: At the time of clinical ablation procedure
Reduction in AF inducibility in silico models following simulated ablation
Time frame: Based on measurements taken during the clinical ablation procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Hypertrophic Cardiomyopathy (HCM)
RecruitingObservational study
HCMR Re-Imaging Study
Hypertrophic Cardiomyopathy (HCM)
Enrolling by invitationPhase 2/3
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Active, not recruitingObservational study
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Hypertrophic Cardiomyopathy (HCM)
Not yet recruitingObservational study
Aficamten and Patient-Reported Outcomes in Real-World nHCM
Hypertrophic Cardiomyopathy (HCM)
Not yet recruiting
Individualized Exercise Training in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertrophic Cardiomyopathy (HCM) and Atrial Fibrillation (AF), run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts (time frame: At the time of the clinical ablation procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.